Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Pharmacy students’ knowledge and attitudes regarding GLP-1 receptor agonist adverse effects in obesity management: a cross-sectional study
The Libyan journal of medicine, 2026;21(1):2749899
Urinary Stone Recurrence After Initiation of GLP-1-Based Therapy: A Romanian Retrospective Cohort Study of Clinical, Renal, and Hydration-Related Factors
Journal of clinical medicine, 2026;15(20)
Biliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors
Journal of clinical medicine, 2026;15(20)
Semaglutide in Patients with Obesity and Psoriasis: Insights from an 18-Month Real-World Experience
Journal of clinical medicine, 2026;15(20)
Comparative Transcriptomic Profiling of Diabetic Wound Responses to Recombinant Periplaneta americana Thymosin Isoforms in Male ob/ob Mice
Genes, 2026;17(10)
Pregnancy and perinatal outcomes following exposure to GLP-1 and dual GLP-1/GIP receptor agonists: a time-window-stratified systematic review and meta-analysis
Frontiers in pharmacology, 2026;17:1994366
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
Frontiers in endocrinology, 2026;17:1977433
Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders
Internal medicine (Tokyo, Japan), 2026
Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis
European journal of preventive cardiology, 2026
A Retrospective Chart Review of Tirzepatide and Semaglutide Use in Prediabetes Management and Cardiometabolic Outcomes in a Rural Primary Care Setting
Journal of doctoral nursing practice, 2026
Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026
Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile
Journal of molecular histology, 2026;57(6)
Advances in disease management and treatment outcomes for obesity and knee osteoarthritis in primary care practice
Current medical research and opinion, 2026;:1-14
GLP-1 receptor agonists in Alzheimer’s disease and MCI: a meta-analysis
Alzheimer's & dementia (New York, N. Y.), 2026;12(4):e70334
Weight-Loss Magnitude, Fat Mass, and Device-Estimated Muscle Mass Loss During Obesity Pharmacotherapy
Journal of clinical medicine, 2026;15(20)
Prevalence and temporal trends of exposure to anti-obesity medications during preconception and pregnancy in a nationwide US claims database, 2018-2023
European journal of obstetrics, gynecology, and reproductive biology, 2026;327:115503
GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?
Acta diabetologica, 2026
GLP-1 Receptor Agonists in Dentistry: Promise, Pitfalls, and Evidence Gaps
Journal of dental research, 2026;:220345261488338
Obesity: oral therapy for those afraid of needles
Expert opinion on pharmacotherapy, 2026
Effects of glucagon-like peptide-1 (GLP-1) mono-agonists on reward processing in animal models: a systematic review
Acta neuropsychiatrica, 2026;38:e55